JP2004507496A - 癌治療のためのアジア酸またはアジアチコサイドの使用。 - Google Patents

癌治療のためのアジア酸またはアジアチコサイドの使用。 Download PDF

Info

Publication number
JP2004507496A
JP2004507496A JP2002522878A JP2002522878A JP2004507496A JP 2004507496 A JP2004507496 A JP 2004507496A JP 2002522878 A JP2002522878 A JP 2002522878A JP 2002522878 A JP2002522878 A JP 2002522878A JP 2004507496 A JP2004507496 A JP 2004507496A
Authority
JP
Japan
Prior art keywords
acid
asiaticoside
cancer
asian
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002522878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507496A5 (enExample
Inventor
オー，セ−キュン
ラ，チョーキュン
アブドゥール　カディール，アジゾル
ング，リーン　テイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2004507496A publication Critical patent/JP2004507496A/ja
Publication of JP2004507496A5 publication Critical patent/JP2004507496A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002522878A 2000-08-29 2001-02-14 癌治療のためのアジア酸またはアジアチコサイドの使用。 Pending JP2004507496A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer
PCT/US2001/040103 WO2002017904A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011256721A Division JP5421340B2 (ja) 2000-08-29 2011-11-24 癌治療のためのアジア酸またはアジアチコサイドの使用。

Publications (2)

Publication Number Publication Date
JP2004507496A true JP2004507496A (ja) 2004-03-11
JP2004507496A5 JP2004507496A5 (enExample) 2008-04-10

Family

ID=19749475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002522878A Pending JP2004507496A (ja) 2000-08-29 2001-02-14 癌治療のためのアジア酸またはアジアチコサイドの使用。
JP2011256721A Expired - Fee Related JP5421340B2 (ja) 2000-08-29 2011-11-24 癌治療のためのアジア酸またはアジアチコサイドの使用。

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011256721A Expired - Fee Related JP5421340B2 (ja) 2000-08-29 2011-11-24 癌治療のためのアジア酸またはアジアチコサイドの使用。

Country Status (9)

Country Link
US (1) US20040097463A1 (enExample)
EP (1) EP1313462B1 (enExample)
JP (2) JP2004507496A (enExample)
AT (1) ATE415962T1 (enExample)
AU (1) AU2001247968A1 (enExample)
DE (1) DE60136826D1 (enExample)
DK (1) DK1313462T3 (enExample)
MY (1) MY138883A (enExample)
WO (1) WO2002017904A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509303A (ja) * 2008-01-11 2011-03-24 シャンハイ・インスティチュート・オブ・ファーマシューティカル・インダストリー（エスアイピーアイ） アジアティック酸（ａｓｉａｔｉｃａｃｉｄ）及びその選択される塩に基づく治療用製剤
JP2013534519A (ja) * 2010-06-10 2013-09-05 インダス バイオテック プライベート リミティド センテラ・アジアティカからの高純度アジアチコサイドの製造法及びその使用法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
KR100571886B1 (ko) 2004-02-23 2006-04-17 학교법인 영남학원 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물
JP2007523956A (ja) 2004-02-25 2007-08-23 ダナ−ファーバー キャンサー インスティテュート インク． 腫瘍細胞増殖を阻害するための方法
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20070010459A1 (en) * 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
US20090018146A1 (en) * 2005-01-27 2009-01-15 Research Development Corporation Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
US9146238B2 (en) 2008-04-16 2015-09-29 The Johns Hopkins University Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
MX341872B (es) 2009-12-21 2016-09-06 Pirelli Proceso y planta para construir llantas.
TR201816243T4 (tr) * 2011-01-31 2018-11-21 Lucolas M D Ltd Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US10357483B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods comprising dosing combinations for reducing undesired humoral immune responses
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3186393A4 (en) * 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3124047A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclic triterpenoids for injection lipolysis
US20180228815A1 (en) * 2016-11-09 2018-08-16 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
WO2020078453A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis
CN109528735B (zh) * 2019-01-30 2021-03-12 中国药科大学 积雪草苷在制备治疗皮肤癌药物中的新用途
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2025188669A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63277691A (ja) * 1987-02-26 1988-11-15 インデナ　エス．ピー．エー． サポニンとりん脂質との複合体及びそれらを含有する薬学的及び化粧用の組成物
WO1998023575A1 (en) * 1996-11-27 1998-06-04 Dong Kook Pharmaceutical Co., Ltd. Asiatic acid derivatives having modified a-ring
WO1998051679A1 (fr) * 1997-05-14 1998-11-19 Lvmh Recherche Esters de tocopherol et leurs utilisations en cosmetique et pharmacie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923414A (en) * 1960-04-13 1963-04-10 Laroche Navarron Lab Therapeutic compositions comprising asiatic and arjunolic acids
EP0383171A3 (en) * 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
JPH08133952A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
AU2005251463A1 (en) * 2004-06-14 2005-12-22 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63277691A (ja) * 1987-02-26 1988-11-15 インデナ　エス．ピー．エー． サポニンとりん脂質との複合体及びそれらを含有する薬学的及び化粧用の組成物
WO1998023575A1 (en) * 1996-11-27 1998-06-04 Dong Kook Pharmaceutical Co., Ltd. Asiatic acid derivatives having modified a-ring
WO1998051679A1 (fr) * 1997-05-14 1998-11-19 Lvmh Recherche Esters de tocopherol et leurs utilisations en cosmetique et pharmacie

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509303A (ja) * 2008-01-11 2011-03-24 シャンハイ・インスティチュート・オブ・ファーマシューティカル・インダストリー（エスアイピーアイ） アジアティック酸（ａｓｉａｔｉｃａｃｉｄ）及びその選択される塩に基づく治療用製剤
JP2013534519A (ja) * 2010-06-10 2013-09-05 インダス バイオテック プライベート リミティド センテラ・アジアティカからの高純度アジアチコサイドの製造法及びその使用法

Also Published As

Publication number Publication date
EP1313462A1 (en) 2003-05-28
DK1313462T3 (da) 2009-03-30
AU2001247968A1 (en) 2002-03-13
DE60136826D1 (de) 2009-01-15
WO2002017904A1 (en) 2002-03-07
MY138883A (en) 2009-08-28
US20040097463A1 (en) 2004-05-20
JP2012092110A (ja) 2012-05-17
EP1313462B1 (en) 2008-12-03
ATE415962T1 (de) 2008-12-15
JP5421340B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
JP5421340B2 (ja) 癌治療のためのアジア酸またはアジアチコサイドの使用。
JP4172726B2 (ja) シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US20080125380A1 (en) Fatty acid-anticancer conjugates and uses thereof
AU720704B2 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
US20030055014A1 (en) Inhibition of angiogenesis by nucleic acids
WO1997044336A9 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
US8349832B2 (en) Compounds and compositions for treating cancer
US20050272703A1 (en) Anti-tumor agents
US8318737B2 (en) Compounds and compositions for treating cancer
CA2373643A1 (en) Anti-tumor comprising boroproline compounds
WO2000067802A1 (en) Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
KR20020000147A (ko) 지방산-항암제 결합체 및 그의 용도
US20050267027A1 (en) Use of erythropoietin for treatment of cancer
US20130237539A1 (en) Compounds and Compositions for Treating Cancer
WO2011028860A2 (en) Compounds and compositions for treating cancer
AU722912C (en) Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
HK1022301B (en) Conjugates of cis-docosahexaenoic acid and paclitaxel

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120821